Moreover, our report underlines – in accordance with previous reports and recommendations [31] – the need to treat MS and NMO, two conditions with substantial differences in pathogenesis [32,33] differentially and, in particular, to avoid treatment with IFN-β in patients with NMO. The gene discussed is IFNB1; the disease is myeloid sarcoma.